Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Joey Cohen
Medication Adherence

Matthew Durham
Omnidynamic Marketing

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy